MedTrace Logo

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

NCT06716281 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2024-12-06

No results posted yet for this study

Summary

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

Conditions

Interventions

BIOLOGICAL

Human umbilical cord mesenchymal stem cells

a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL

BIOLOGICAL

Placebo

Sodium Chloride Injection

Sponsors & Collaborators

  • Shanghai IxCell Biotechnology Co., LTD

    lead OTHER

Principal Investigators

  • Jie Zhao · The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-05
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716281 on ClinicalTrials.gov